Immunomedics, Inc., (Nasdaq: IMMU) – IMMU creates new Immunoconjugates

Immunomedics, Inc. is a unique biopharmaceutical company that is chiefly involved in creating therapeutic agents that primarily involve monoclonal antibody technology. 

IMMU has modified a known drug that destroys cancer cells (new SN-38 derivatives).  It has attached this molecule to an antibody it has designed to find and attach to pancreatic, lung and colon cancer cells (Immunoconjugate).  The drug/antibody combination targeted towards colon cancer cells  (labetuzumab-SN-38 conjugate) has shown promise in animal models.

Infact, IMMU has six drug/antibody combinations in the works, they are:

Epratuzumab and 90Y-epratuzumab in non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia

Veltuzumab in NHL.

90Y-PAM4 in pancreatic cancer.

Milatuzumab in NHL, chronic lymphocytic leukemia, and multiple myeloma.

131I-labetuzumab as an adjuvant therapy in metastatic colorectal cancer.

These potential agents may make this company more profitable in the future.

Immunomedics, Inc., (Nasdaq: IMMU) – Increased In Price Since Last Update (3/18)

We here at STOCKMD pride ourselves on providing quality information on bio-pharmaceutical companies. 

We informed you that IMMU got orpan status for its new drug Milatuzumab on March 18, 2008.  Since then the stock price has increased from 2.2 to 2.7 today.  That is a 22% increase in price despite this bearish market in which we find ourselves.  We hope all of you are doing well and we wish you good fortune in trading.

Immunomedics, Inc., (Nasdaq: IMMU) – Milatuzumab granted orphan drug designation

March 18, 2008

Immunomedics, Inc. is a unique biopharmaceutical company that is chiefly involved in creating therapeutic agents that primarily involve monoclonal antibody technology. 

Immunomedics, Inc, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to milatuzumab for the treatment of multiple myeloma.

The above designation allows IMMU to monopolize the use of milatuzumab for multiple myeloma for 7 years upon final approval by the FDA.  There are additional financial benefits that are included when a drug is given orphan status which includes:

Waiver of Prescription Drug User Fee Act (PDUFA) and filing fees.

IMMU will also recieve tax credits for the costs of clinical research, and assistance in clinical research study designs.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)-Telaprevir; New Hepatitis C Drug, Phase III Clinical Trial Initiated.

Vertex Pharmaceuticals and Tibotec revealed that they will  initiate “ADVANCE”, a Phase 3 Clinical Study with Telaprevir in the Treatment-Naive, Genotype 1 Hepatitis C Patients.

This drug is unique because it is the first of a class of anti-viral drugs known as protease inhibitors (also used in HIV) to reach phase 3 clinical trials.

If the results of this phase 3 trial are good then this company may very well increase its profitability and may lead to price movement.